Agios Pharmaceuticals (AGIO) Capital Expenditures (2012 - 2026)
Agios Pharmaceuticals (AGIO) posted Capital Expenditures of $769000.0 for Q1 2026, up 1550.94% on a QoQ basis from -$53000.0 in Q4 2025, and little changed year-over-year from $766000.0 in Q1 2025.
Agios Pharmaceuticals (AGIO) Capital Expenditures (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals' Capital Expenditures history runs 15 years deep, the most recent figure standing at $769000.0 for Q1 2026.
- Quarterly Capital Expenditures changed 0.39% year-over-year to $769000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $286000.0 (down 88.33% YoY) and the FY2025 annual result came in at $283000.0, down 83.2% from the prior year.
- Capital Expenditures was $769000.0 for Q1 2026 at Agios Pharmaceuticals, up from -$53000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $4.8 million in Q3 2022 and bottomed at -$4.6 million in Q4 2022.
- A 5-year average of $243375.0 and a median of $220500.0 in 2023 frame the typical range for Capital Expenditures.
- Peak annual rise in Capital Expenditures reached 1983.33% in 2025, while the deepest fall reached 6968.42% in 2025.
- Agios Pharmaceuticals' Capital Expenditures stood at -$4.6 million in 2022, then surged by 121.37% to $985000.0 in 2023, then soared by 64.87% to $1.6 million in 2024, then plunged by 103.26% to -$53000.0 in 2025, then jumped by 1550.94% to $769000.0 in 2026.
- Business Quant data shows AGIO's Capital Expenditures at $769000.0 in Q1 2026, -$53000.0 in Q4 2025, and -$1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -8,939.03 |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 43.25 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 133.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 230.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 786,000.00 |
| 10 | Agios Pharmaceuticals | 2.13 Bn | 2.13 Bn | 19.43 Mn | 769,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 769,000.00 |
| Mar 31, 2026 | 769,000.00 |
| Dec 31, 2025 | -53,000.00 |
| Dec 31, 2025 | -53,000.00 |
| Sep 30, 2025 | -1.31 Mn |
| Sep 30, 2025 | -1.31 Mn |
| Jun 30, 2025 | 875,000.00 |
| Jun 30, 2025 | 875,000.00 |
| Mar 31, 2025 | 766,000.00 |
| Mar 31, 2025 | 766,000.00 |
| Dec 31, 2024 | 1.62 Mn |
| Dec 31, 2024 | 1.62 Mn |
| Sep 30, 2024 | 19,000.00 |
| Sep 30, 2024 | 19,000.00 |
| Jun 30, 2024 | 42,000.00 |
| Jun 30, 2024 | 42,000.00 |
| Dec 31, 2023 | 985,000.00 |
| Dec 31, 2023 | 985,000.00 |
| Sep 30, 2023 | 8,000.00 |
| Sep 30, 2023 | 8,000.00 |